Fate Therapeutics Inc
FATE
Company Profile
Business description
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Contact
12278 Scripps Summit Drive
San DiegoCA92131
USAT: +1 858 875-1800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
181
Stocks News & Analysis
stocks
Potentially catastrophic ruling for ASX company
We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks
4 charts on Nvidia’s record $4 trillion market cap
Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
stocks
Could merger breathe new life into struggling ASX asset manager?
Platinum’s board voted unanimously in favour of a merger we expect would be value accretive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,815.30 | 5.00 | -0.06% |
CAC 40 | 7,808.17 | 21.12 | -0.27% |
DAX 40 | 24,160.64 | 94.67 | -0.39% |
Dow JONES (US) | 44,392.41 | 20.90 | 0.05% |
FTSE 100 | 8,998.06 | 56.94 | 0.64% |
HKSE | 24,203.32 | 63.75 | 0.26% |
NASDAQ | 20,638.02 | 52.49 | 0.26% |
Nikkei 225 | 39,459.62 | 110.06 | -0.28% |
NZX 50 Index | 12,678.69 | 7.99 | -0.06% |
S&P 500 | 6,264.36 | 4.61 | 0.07% |
S&P/ASX 200 | 8,570.40 | 9.70 | -0.11% |
SSE Composite Index | 3,519.65 | 9.47 | 0.27% |